New stock news | Huajian's future Hong Kong IPO and the "full circulation" of domestically unlisted shares have been approved by the China Securities Regulatory Commission.

On May 9th, the International Cooperation Department of the China Securities Regulatory Commission issued the "Filing Notice on the Overseas Issuance and Listing of Huajian Future (Chengdu) Technology Co., Ltd. and the "Full Circulation" of Unlisted Shares in the Domestic Market". The company plans to issue no more than 22,999,800 overseas listed common shares and list them on the Hong Kong Stock Exchange. 23 shareholders of the company intend to convert a total of 59,999,605 unlisted domestic shares into overseas listed shares and list them for circulation on the Hong Kong Stock Exchange. According to public information, Huajian Future was established in 2017, headquartered in Wenjiang District, Chengdu, and is a biopharmaceutical technology company specializing in the research and production of innovative small molecule chemical drugs. The company is dedicated to the research and development of new drugs for major clinical needs, with core product layout focusing on next-generation tumor microenvironment therapy and the treatment of complex metabolic diseases. The company has established a complete drug development platform covering drug design and synthesis, screening and evaluation, quality analysis, pharmacology and efficacy, and formulation development.